PeproMene Bio Overview

  • Year Founded
  • 1913

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Financing Rounds
  • 6

  • Investments
  • 1

PeproMene Bio General Information

Description

Developer of immunotherapy products designed to treat cancers and immune disorders. The company's technology targets B-cell activating factor receptors, addresses CD19-resistant models, utilizes novel antibody technology, treats relapsed B-cell malignancies, provides durable complete responses, and overcomes tumor antigen loss, providing healthcare providers with treatments for patients with unmet medical needs.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Corporate Office
  • 15375 Barranca Parkway
  • Suite A211
  • Irvine, CA 92618
  • United States
+1 (949)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Corporate Office
  • 15375 Barranca Parkway
  • Suite A211
  • Irvine, CA 92618
  • United States
+1 (949)

PeproMene Bio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PeproMene Bio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore PeproMene Bio‘s full profile, request access.

Request a free trial

PeproMene Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PeproMene Bio Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore PeproMene Bio‘s full profile, request access.

Request a free trial

PeproMene Bio Investments (1)

PeproMene Bio’s most recent deal was a PIPE with Binex (Busan) for . The deal was made on 21-Mar-2018.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Binex (Busan) 21-Mar-2018 PIPE Other Pharmaceuticals and Biotechnology
To view PeproMene Bio’s complete investments history, request access »

PeproMene Bio FAQs

  • When was PeproMene Bio founded?

    PeproMene Bio was founded in 1913.

  • Where is PeproMene Bio headquartered?

    PeproMene Bio is headquartered in Irvine, CA.

  • What is the size of PeproMene Bio?

    PeproMene Bio has 7 total employees.

  • What industry is PeproMene Bio in?

    PeproMene Bio’s primary industry is Drug Discovery.

  • Is PeproMene Bio a private or public company?

    PeproMene Bio is a Private company.

  • What is PeproMene Bio’s current revenue?

    The current revenue for PeproMene Bio is .

  • How much funding has PeproMene Bio raised over time?

    PeproMene Bio has raised $50.2M.

  • Who are PeproMene Bio’s investors?

    Institute for Follicular Lymphoma Innovation, KB Investment, Seven Tree Equity Partners, Binex (Busan), and Solidus Investment have invested in PeproMene Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process